皮肤 T 细胞淋巴瘤治疗：5-氟尿嘧啶瘤内注射联合咪喹莫特外用治疗的病例系列。

Cutaneous T-Cell Lymphoma Treatment: Case Series of Combination Therapy With Intralesional Injections of 5-Fluorouracil and Topical Imiquimod.

机构信息

Dr. Lindberg is from the Georgetown University School of Medicine, Washington, DC. Drs. DiLorenzo and DeSimone are from the Department of Dermatology, MedStar Washington Hospital Center/Georgetown University Hospital, and the Department of Dermatology, Georgetown University. Dr. DeSimone is from the INOVA Schar Cancer Institute, Fairfax, Virginia.

出版信息

Cutis. 2023 Jan;111(1):E19-E25. doi: 10.12788/cutis.0697.

DOI:10.12788/cutis.0697

PMID:36947768

Abstract

Cutaneous T-cell lymphoma (CTCL) is a chronic form of skin cancer. Skin-directed therapies rarely achieve complete clearance of lesions, and recurrences are frequent. In this case series, 9 patients with stage IA to IVA2 CTCL received intralesional (IL) therapy with 5-fluorouracil (5-FU) and imiquimod (IMQ) cream 5% daily to recalcitrant plaques and tumors. All 9 patients attained a complete response (CR) with no recurrences reported and no severe side effects. We find that combination IL 5-FU and IMQ cream 5% daily is a well-tolerated, effective, and durable skin-directed therapy for recalcitrant plaques and tumors in CTCL.

摘要

皮肤 T 细胞淋巴瘤（CTCL）是一种慢性皮肤癌。皮肤靶向治疗很少能完全清除病变，且经常复发。在本病例系列中，9 名 IA 期至 IVA2 期 CTCL 患者接受了局部（IL）治疗，用 5-氟尿嘧啶（5-FU）和咪喹莫特（IMQ）乳膏 5%每日治疗顽固斑块和肿瘤。所有 9 名患者均获得完全缓解（CR），无复发，无严重副作用。我们发现，联合局部注射 5-FU 和 IMQ 乳膏 5%每日治疗顽固斑块和肿瘤是一种耐受性良好、有效且持久的 CTCL 皮肤靶向治疗方法。